Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALS
2022 · New England Journal of Medicine · 763 citations
https://doi.org/10.1056/nejmoa2204705
P
Peng Sun
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
179
Papers
3.5K
Citations
29
h-index
59
i10-index
Peng Sun is an academic researcher from Binzhou University. The author has contributed to research in topics: Lymphoma Diagnosis and Treatment & Viral-associated cancers and disorders & Neurogenetic and Muscular Disorders Research. The author has an h-index of 29, co-authored 153 publications.
ORCID: 0000-0003-3811-0371Papers by this author
worksDesign of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study
2022 · Neurotherapeutics · 158 citations
https://doi.org/10.1007/s13311-022-01237-4
The ratio of hemoglobin to red cell distribution width as a novel prognostic parameter in esophageal squamous cell carcinoma: a retrospective study from southern China
2016 · Oncotarget · 130 citations
https://doi.org/10.18632/oncotarget.9516
Racial patterns of patients with primary mediastinal large B-cell lymphoma
2016 · Medicine · 42 citations
https://doi.org/10.1097/md.0000000000004054
EEG biofeedback improves attentional bias in high trait anxiety individuals
2013 · BMC Neuroscience · 38 citations
https://doi.org/10.1186/1471-2202-14-115
Short Course Radiation in the Treatment of Localized Rectal cancer: A Systematic Review and Meta-Analysis
2015 · Scientific Reports · 30 citations
https://doi.org/10.1038/srep10953
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat